On July 11, Quantinuum declined 5.33% in regular trading, trading at $69.69/share, with turnover of $67.38 million.

On the news front, since multiple top-tier Wall Street banks initiated coverage on June 29, the stock has experienced persistent wide-range volatility driven by sharp valuation disagreements. Target prices span from Morgan Stanley's $78 (Equal-weight) to Rosenblatt's $155 (Buy), with JPMorgan at $97, BofA Securities and Needham at $100, UBS at $93, and Mizuho, Cantor Fitzgerald, and Jefferies at $90 — reflecting a near-double gap between the highest and lowest targets that underscores fundamental disagreement over quantum computing commercialization prospects.

Compounding the pressure, the company listed barely over a month ago at $60/share and reported Q1 revenue of just $5.24 million, down 73% year-over-year, with net losses widening to $136.5 million. These weak fundamentals combined with the wide analyst valuation spread continue to drive elevated short-term price swings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)